> ## Content Index
> Fetch the complete content index at: https://blog.novellia.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# How Patient Experience Has Shaped Medicine Through Real World Data
- URL: https://blog.novellia.com/how-patient-experience-has-shaped-medicine-through-real-world-data/
- Published: 2026-11-06T13:59:00.000Z
- Updated: 2026-11-06T13:59:00.000Z
- Author: Team Novellia

*Posted: November 6, 2026*

*By: Cait Williamson PhD*

Every time you pick up a medication from your pharmacy, track your steps with a smartwatch, or fill out a health questionnaire, you're adding to something bigger than your own medical records. That "something bigger" is called real-world data, and real-world evidence (the conclusions researchers draw from it) has quickly been one of the most powerful forces in modern medicine for nearly a century. 

In this post, we'll trace how real-world data has shaped the drugs that get approved and who can access them and how we learn more about risk factors and fighting disease.

## **What is real-world data, and why does it matter to patients?**

Real-world data (RWD) is health information collected outside the controlled setting of a clinical trial. It comes from electronic health records, insurance claims, patient registries, pharmacy records, wearable devices, and even surveys patients fill out about how they're actually feeling day to day. When researchers analyze that data to answer a question, such as how well a drug works in everyday use or how a disease progresses across thousands of real patients, the resulting conclusions are called real-world evidence (RWE).

The distinction from clinical trial data matters. Clinical trials are tightly controlled and answer the question “does this treatment work under ideal conditions?” Real-world data answers a different, equally important question: “what actually happens when this treatment reaches the full, messy diversity of real patients in their daily lives?” The two approaches complement each other, and over the past 75 years, real-world data has repeatedly filled in gaps that trials alone couldn't.

## **Before the term *real-world evidence* existed: the Framingham Heart Study**

In 1948, the federal government began following more than 5,000 residents of Framingham, Massachusetts, checking in on their health every few years for the rest of their lives, in what became the [Framingham Heart Study](https://www.framinghamheartstudy.org/fhs-about/history/?ref=blog.novellia.com).

At the time, heart disease was the leading cause of death in the United States, and doctors had no real sense of what caused it or how to prevent it. By tracking this community's real, everyday health outcomes over decades, researchers identified the factors we now take for granted: high blood pressure, high cholesterol, smoking, obesity, and physical inactivity. The Framingham Heart Study is where the term “risk factor” was coined, and it reshaped how every doctor in the country approaches a routine physical. It remains one of the clearest examples of real-world patient data changing the entire practice of medicine.

## **Real-world evidence becomes official policy**

For most of this history, real-world data was used informally, through public health surveillance and academic research, rather than through any formal regulatory process. That changed in 2016, when Congress passed the [21st Century Cures Act](https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence?ref=blog.novellia.com), which directed the FDA to formally evaluate how real-world data and real-world evidence could support drug approvals and safety decisions. The FDA published its official [Real-World Evidence Framework](https://www.fda.gov/media/120060/download?ref=blog.novellia.com) in December 2018, and by then it had already been running the [Sentinel Initiative](https://www.fda.gov/safety/fdas-sentinel-initiative?ref=blog.novellia.com), a large-scale system for monitoring drug safety using real-world insurance claims and medical record data, for about a decade. Now, life science companies that develop drugs don’t just have real world evidence as a “nice to have,” but it is necessary for better understanding how their medication works in the real world, outside of a clinical trial setting. 

## **How real world evidence expanded who a drug can help: the Ibrance story**

One of the clearest recent examples of real-world data changing patient access came in 2019, with a breast cancer drug called [Ibrance (palbociclib)](https://www.pfizer.com/news/press-release/press-release-detail/u%5Fs%5Ffda%5Fapproves%5Fibrance%5Fpalbociclib%5Ffor%5Fthe%5Ftreatment%5Fof%5Fmen%5Fwith%5Fhr%5Fher2%5Fmetastatic%5Fbreast%5Fcancer?ref=blog.novellia.com). Ibrance had been approved in 2015 for women with a certain type of advanced breast cancer, based on standard clinical trials. But breast cancer in men is rare, accounting for less than 1 percent of all cases, and clinical trials studying the drug had excluded men almost entirely. As a result, men with the same type of breast cancer who wanted to try Ibrance could only get it off-label, without a formal approval behind that use.

Rather than run a brand-new clinical trial for a tiny patient population, Pfizer pulled together real-world data: electronic health records and insurance claims showing how men were already being treated with Ibrance in actual clinical practice, plus safety reports collected along the way. The FDA reviewed that real-world evidence and used it to formally expand Ibrance's approval to include men, becoming one of the first drugs in the country to gain a new patient population this way. It meant men with this rare form of breast cancer finally had an approved, on-label option, built entirely from the experience of patients who came before them.

## **What this means for you today**

Each of these moments, a small New England town's health records that informed heart attack risk factors, to a drug label expansion, started with ordinary patients going about their care and, in some way, having that experience recorded. None of them would have been possible without real people's health data being collected, organized, and eventually studied.

That's still just as true today. Registries and real-world data projects are what help researchers understand how rare diseases progress, how well treatments work outside the tightly controlled world of a clinical trial, and who's being left out of the evidence base entirely. If you're living with a health condition, the details of your own experience, including things that never make it into a clinical trial report, are part of exactly the kind of data that has been moving medicine forward for 75 years. You can learn more about clinical research studies on the [Novellia ](https://blog.novellia.com/)[blog](http://blog.we/?ref=blog.novellia.com). We also currently have clinical research studies available for patients to join!

---

**Sources**

- [Framingham Heart Study: History](https://www.framinghamheartstudy.org/fhs-about/history/?ref=blog.novellia.com)
- [CDC: Polio and the Epidemic Intelligence Service (The Cutter Incident)](https://www.cdc.gov/museum/online/story-of-cdc/polio/index.html?ref=blog.novellia.com)
- [CDC: History of Measles](https://www.cdc.gov/measles/about/history.html?ref=blog.novellia.com)
- [FDA: Real-World Evidence](https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence?ref=blog.novellia.com)
- [FDA: Framework for FDA's Real-World Evidence Program (Dec. 2018)](https://www.fda.gov/media/120060/download?ref=blog.novellia.com)
- [FDA: Sentinel Initiative](https://www.fda.gov/safety/fdas-sentinel-initiative?ref=blog.novellia.com)
- [Pfizer: FDA Approves Ibrance for Men with HR+, HER2- Metastatic Breast Cancer](https://www.pfizer.com/news/press-release/press-release-detail/u%5Fs%5Ffda%5Fapproves%5Fibrance%5Fpalbociclib%5Ffor%5Fthe%5Ftreatment%5Fof%5Fmen%5Fwith%5Fhr%5Fher2%5Fmetastatic%5Fbreast%5Fcancer?ref=blog.novellia.com)

---

**About Novellia: Novellia is a patient health platform that helps people consolidate their medical records, understand their health data, and participate in research studies on their own terms. Patients stay in control of their data at every step.**